Zafgen (ZFGN) began trading on the NASDAQ on 19 June 2014

Zafgen (ZFGN), a biotech developing a treatment for severe obesity and hunger-related disorders

Offered 5.0 million shares 

Zafgen was founded in 2005 in Cambridge, MA. 

Leerink Partners and Cowen & Company are the joint bookrunners on the deal.

Description

Zafgen, Inc. is a biopharmaceutical company. The Company is engaged in improving the health and well-being of patients affected by obesity. Beloranib, the Company’s product candidate, is a twice-weekly subcutaneous injection being developed for the treatment of multiple indications, including obesity and hyperphagia, or insatiable life-threatening hunger and hunger-related behaviors, in Prader-Willi Syndrome (PWS), craniopharyngioma-associated obesity, and severe obesity in the general population. PWS is a rare and complex genetic disorder characterized by physiologic, cognitive and behavioral symptoms, including hyperphagia and obesity. Craniopharyngioma is a rare form of benign brain tumor that occurs near the optic nerve, pituitary gland and hypothalamus. Approximately 30% to 50% of cases of craniopharyngioma are diagnosed in childhood and adolescence.

Address

8TH FLOOR, ONE BROADWAY
CAMBRIDGE, MA 02142
United States 

Key stats and ratios

	Q1 (Mar '14)	2013
Net profit margin	-	-
Operating margin	-	-
EBITD margin	-	-
Return on average assets	-45.00%	-57.11%
Return on average equity	-	-
Employees	10